Vol.

No.

March 15, 2024Mar 15, 2024

DOWNLOAD THE PDF

FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC Pooled analysis finds correlations between early endpoints and OS in ICI trials

Cover Story

Conversation with The Cancer Letter Regulatory News

FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC

Pooled analysis finds correlations between early endpoints and OS in ICI trials

By Matthew Bin Han Ong and Paul Goldberg

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Regulatory News

ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

By Jacquelyn Cobb and Paul Goldberg

White House

Biden’s FY25 budget requests $522M increase for NCI, $1.5B for ARPA-H, $2.9B for Moonshot

By Alexandria Carolan

Guest Editorial

How to navigate early clinical development and support robust registrational strategy and late-stage development in oncology

By Tanja Obradovic

Free In the Archives

Women’s History Month: How women in oncology are fighting for cultural change

In Brief

Lillian Siu named 2024-2025 president-elect of AACR

Hidalgo, Paskett, Politi, Soria, Wu named to AACR board

Wake Forest’s Nadine Barrett named ACCC president; 2024-2025

Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s

Aleksandar Sekulic named director of dermatology and translational research at City of Hope Phoenix

Tampa General Hospital Cancer Institute opens phase I unit

Thyme Care creates Thyme Care Oncology Partners, with over 400 oncologists nationwide

Cancer Center at Illinois researchers receive $650,000 Convergence Accelerator Grant from NSF

Jasper Health, LLS collaborate to support blood cancer patients

Clinical Roundup

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Cancer Center at Illinois Chan Lab develops therapeutic to reduce side effects of cancer treatment

SWOG pilot study confirms feasibility, acceptability of bowel symptom intervention studies

ASCO calls for global equity in cancer clinical trials

IARC publishes report on the intergenerational impact of cancer deaths in women

Drugs & Targets

FDA approves Breyanzi CAR T-cell therapy in adults with R/R/ CLL or SLL

FDA approves Tevimbra in advanced or metastatic esophageal squamous cell carcinoma indication

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 06 - February 13, 2026